Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Plasma cell 1NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Desipramine × NET × Clear all
NCT01719861 2017-04-17

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
6 enrolled 12 charts
EndocrineNETThoracic

Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡